Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11165466 | 1.00 | CTSL (0.53) | CTSLSIRT2SYKCTSKCTSS | |
| SCHEMBL14295020 | 1.00 | CTSL (0.53) | CTSLSIRT2SYKCTSKCTSS | |
| SCHEMBL25907874 | 0.92 | SYK (0.54) | CTSLSYKCTSKCTSSCTSB | |
| SCHEMBL25907875 | 0.92 | SYK (0.54) | CTSLSYKCTSKCTSSCTSB | |
| SCHEMBL11599337 | 0.91 | PPARA (0.53) | CTSLSIRT2SYKCTSKCTSS | |
| SCHEMBL14997847 | 0.91 | PPARA (0.53) | CTSLSIRT2SYKCTSKCTSS | |
| SCHEMBL10887447 | 0.91 | PPARA (0.53) | CTSLSIRT2SYKCTSKCTSS | |
| SCHEMBL13570899 | 0.91 | SYK (0.55) | CTSLSYKCTSKCTSSCTSB | |
| SCHEMBL13570900 | 0.91 | SYK (0.55) | CTSLSYKCTSKCTSSCTSB | |
| SCHEMBL2776833 | 0.91 | PPARA (0.55) | CTSLSIRT2SYKCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| CN-118324742-A | Solid forms comprising oxoisoindole compounds and salts thereof, compositions comprising them and methods of their use | 细胞基因公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118178417-A | Antiproliferative compounds and second active agents for the treatment of multiple myeloma | 细胞基因公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114409630-B | Pharmaceutical compositions comprising oxoisoindole compounds and methods of using the same | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114394954-B | Solid forms comprising oxoisoindole compounds and salts thereof, compositions comprising them and methods of their use | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116744925-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-110869021-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-114667147-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-113597301-A | Pharmaceutical compositions comprising (S) -4- (4- (4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) piperazin-1-yl) -3-fluorobenzonitrile and methods of using the same | 细胞基因公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113597425-A | Solid forms comprising (S) -4- (4- (4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) piperazin-1-yl) -3-fluorobenzonitrile and salts thereof, as well as compositions comprising and methods of using the same | 细胞基因公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113543786-A | Antiproliferative compounds and second agents for the treatment of multiple myeloma | 细胞基因公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113164775-A | Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846907-A1 | POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-112492874-A | Treatment of multiple myeloma and use of biomarkers for 4- (4- (4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) piperazin-1-yl) -3-fluorobenzonitrile | 细胞基因公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-112399848-A | Anti-proliferative compounds and bispecific antibodies against BCMA and CD3 for use in combination | 细胞基因公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| CN-110869021-A | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CTSL 2695/4885SIRT2 4183/4885SYK 3033/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | CTSL 2695/4885SIRT2 4183/4885SYK 3033/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CTSL 2695/4885SIRT2 4183/4885SYK 3033/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | CTSL 2695/4885SIRT2 4183/4885SYK 3033/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CTSL 1792/4885SIRT2 4473/4885SYK 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.